Selecting and Sequencing Therapies to Improve Outcomes in Patients With Lymphoma

Video

Key opinion leaders describe when to refer a patient with lymphoma and at what point treatments should be switched, and the evolution of T-cell engaging therapies.

Related Videos
Experts on MM
A panel of 4 experts on multiple myeloma seated at a long table
Experts on MM
A panel of 4 experts on multiple myeloma seated at a long table
Experts on NSCLC
Experts on NSCLC
A panel of 4 experts on multiple myeloma seated at a long table
A panel of 4 experts on multiple myeloma seated at a long table
Experts on MM
Related Content
Data from the phase 1/2 EPCORE NHL-1 trial support the FDA breakthrough therapy designation for epcoritamab-bysp in patients with previously treated relapsed/refractory follicular lymphoma.

Epcoritamab Earns FDA BTD in Relapsed/Refractory Follicular Lymphoma

November 28th 2023
Article

Data from the phase 1/2 EPCORE NHL-1 trial support the FDA breakthrough therapy designation for epcoritamab-bysp in patients with previously treated relapsed/refractory follicular lymphoma.

Oncology Peer Review On-The-Go: Current Treatments in Peripheral T-cell Lymphoma

Oncology Peer Review On-The-Go: Current Treatments in Peripheral T-cell Lymphoma

August 23rd 2022
Podcast

Robert Stuver, MD, and Zachary D. Epstein-Peterson, MD, spoke with CancerNetwork® about a review article on the treatment of peripheral T-cell lymphoma published in the journal ONCOLOGY®.

The primary end point of overall response rate is met in the phase 2 ROSEWOOD study of patients with relapsed/refractory follicular lymphoma receiving zanubrutinib plus obinutuzumab vs obinutuzumab monotherapy.

Zanubrutinib Combo Improves ORR Vs Obinutuzumab in Follicular Lymphoma

October 24th 2023
Article

The primary end point of overall response rate is met in the phase 2 ROSEWOOD study of patients with relapsed/refractory follicular lymphoma receiving zanubrutinib plus obinutuzumab vs obinutuzumab monotherapy.

Managing Cytokine Release Syndrome in Patients on CAR T-Cell Therapy

Managing Cytokine Release Syndrome in Patients on CAR T-Cell Therapy

May 29th 2019
Podcast

Ahead of the ASCO Annual Meeting, we discuss the assessment and management of cytokine release syndrome in patients with cancer with Elizabeth Shpall, MD.

A frontline treatment regimen including bortezomib and rituximab appears to be well tolerated among patients with B-cell non-Hodgkin marginal zone lymphoma in a phase 2 study.

Bortezomib Regimen Yields Responses in B-Cell Marginal Zone Lymphoma

October 23rd 2023
Article

A frontline treatment regimen including bortezomib and rituximab appears to be well tolerated among patients with B-cell non-Hodgkin marginal zone lymphoma in a phase 2 study.

Treatment with EX103 produces deep responses among heavily pretreated patients with B-cell non-Hodgkin lymphoma across multiple subgroups in a phase 1 trial.

EX103 Yields Preliminary Activity, Tolerability in R/R Non-Hodgkin Lymphoma

October 23rd 2023
Article

Treatment with EX103 produces deep responses among heavily pretreated patients with B-cell non-Hodgkin lymphoma across multiple subgroups in a phase 1 trial.